OrthoPediatrics Corp.
KIDSHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeOrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic. The $585.1M market capitalization puts KIDS squarely in small-cap range for its industry. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products.
Market Cap
$585.1M
Beta
0.98
P/E (TTM)
—
P/E (Fwd)
-31.56
EPS (TTM)
$-1.68
EPS (Fwd)
$-0.71
ROE
-11.4%
ROA
-2.8%
Cash
$45.9M
Total Debt
$111.2M
Free CF
$3.2M
52W Change
9.4%
Annual Financials
Cash vs Debt
Where KIDS stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, KIDS finished 27.56% above its 150-day moving average ($18.54) and 28.60% above its 200-day moving average ($18.39). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KIDS overbought or oversold?
At the August 31, 2026 close, KIDS's RSI(14) was 52.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, KIDS has $45.9M in cash with $111.2M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $3.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -11.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $122.3M (2022) to $236.3M (2025), reflecting a 93% increase over the period.
As with any equity investment, KIDS carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence OrthoPediatrics Corp.'s trajectory.